Rho Kinase (ROCK) Inhibitors for the Treatment of Glaucoma
Junhui Wu, Jing Wei, Haoliang Chen, Yalong Dang, Lei Fang, Fang Lei
Abstract
Glaucoma is the most common cause of irreversible blindness worldwide. It is characterized by progressive optic nerve degeneration and loss of visual field. Pathological increased intraocular pressure is its main modifiable risk factor. Rho kinase inhibitors are developed as a new class of glaucoma medication that increases outflow facility from the conventional aqueous humor outflow pathway. Additionally, they also have neuroprotective and anti-scarring effects that can might increase the success rate of glaucoma filtration surgery. This review aims to summarize the current concept of Rho kinase inhibitors in the treatment of glaucoma from beach to bedside.
Topics & Concepts
GlaucomaRho-associated protein kinaseMedicineKinasePharmacologyOphthalmologyBiologyCell biologyGlaucoma and retinal disordersNeurological Disorders and TreatmentsSaffron Plant Research Studies